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Abstract: As of late, polyphenols have increasingly interested the scientific community due to their
proposed health benefits. Much of this attention has focused on their bioavailability. Polyphenol–gut
microbiota interactions should be considered to understand their biological functions. The dichotomy
between the biotransformation of polyphenols into their metabolites by gut microbiota and the
modulation of gut microbiota composition by polyphenols contributes to positive health outcomes.
Although there are many studies on the in vivo bioavailability of polyphenols, the mutual relationship
between polyphenols and gut microbiota is not fully understood. This review focuses on the
biotransformation of polyphenols by gut microbiota, modulation of gut microbiota by polyphenols,
and the effects of these two-way mutual interactions on polyphenol bioavailability, and ultimately,
human health.
Keywords: polyphenols; phenolics; flavonoids; gut microbiota; microbial metabolism; bioavailability;
health; interactions
1. Introduction
Polyphenols are secondary metabolites found abundantly in a wide variety of foods, such as fruits,
vegetables, herbs, seeds and cereals, and in beverages, such as coffee, tea, cocoa and wine [1]. They
are currently a topic of great scientific attention due to the interest in their potential health benefits,
which include anti-cancer, anti-oxidant, anti-microbial, anti-inflammatory properties. Polyphenols are
also implicated in preventing chronic diseases such as cardiovascular diseases, diabetes, obesity, and
neurodegenerative diseases, among others [2–5].
Possible beneficial effects of polyphenols are determined by their bioavailability, among which
considerable differences have been observed [6]. Bioavailability is affected by many physicochemical
factors such as the type of bioactive compounds, their polarity, molecular mass, plant matrix, their solid
state (crystalline vs. amorphous), and digestibility by gastrointestinal enzymes, and absorption into the
enterocytes. Bioaccessibility, the determinant of release and solubility of bioactive compounds during
digestion for further uptake and absorption, is another important factor for bioavailability [7]. In order
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to understand bioavailability of phenolic compounds and their potential benefits, determination of
bioaccessibility during digestion is important.
Most polyphenols pass through the small intestine without being absorbed, thus encountering
the gut microbiota which colonizes the colon [8]. This has led to the development of a two-way mutual
reaction between polyphenolic compounds and gut microbiota. First, polyphenols are biotransformed
into their metabolites by gut microbiota that results in the increased bioavailability of polyphenols.
Second, polyphenols modulate the composition of the gut microbial community mostly through the
inhibition of pathogenic bacteria and the stimulation of beneficial bacteria. In the latter, they may act
as a prebiotic metabolite and enrich the beneficial bacteria [9]. Therefore, the interactions of dietary
polyphenols and gut microbiota may result in impact on human host health.
Due to the recent attention paid to these interactions, a number of important reviews have been
published focusing on both ends of the relationship—the effect of phenolics on the gut microbiota
composition, and the effect of gut microbiota on the biotransformation of phenolic compounds, their
bioavailability, or human health [10–19]. The aim of this review is to provide an overview of the
two-way reciprocal relationship of all the sub-classes of phenolic compounds and gut microbiota and
the relevance of these interactions to bioavailability and human health.
2. Polyphenols, Gut Microbiota and Health
Polyphenols are a large group of heterogeneous compounds characterized by hydroxylated
phenyl moieties, and are found mostly in plants, including fruits, vegetables, and cereals,
as well as derived beverages such as tea, coffee and wine [20]. Polyphenols have become
an intense focus of research due to their potential benefits to health, particularly in relation
to the prevention of cancer [21,22] and cardiovascular diseases [23,24]. Suggested beneficial
effects are anticarcinogenic [25,26], antiatherogenic [27,28], antiulcer [29], antithrombotic [30,31],
anti-inflammatory [32,33], antiallergenic [34,35], anticoagulant [36], immune modulating [37],
antimicrobial [38,39], vasodilatory [40], and analgesic activities [41]. To achieve these health benefits,
polyphenols require in situ processing by the gut microbiota to be transformed into a potentially more
bioactive, low-molecular-weight metabolite [42]. Faria et al. (2014) reviewed that total polyphenol
absorption in the small intestine is relatively low (5%–10%) in comparison to other macro- or
micronutrients. The remaining 90%–95% of polyphenols transit to the large intestinal lumen and
accumulate in the millimolar range. From the lumen, together with conjugates excreted from bile, they
are exposed to the enzymatic activities of the gut microbiota [43].
The microbiota that colonize the distal regions of the colon represent the highest concentration of
microorganisms found in human body, as well as the most diverse [44]. It is known that the human
gut has an ecosystem of around 1013–1014 bacterial cells, an estimate 10 times that of human somatic
cells [45]. In addition, the aggregate microbial genome (i.e., microbiome) is predicted to contain more
than three million genes, or 150 times more than human genes [46]. In short, the gut microbiota is
essential for the maintenance of intestinal homeostasis and human health [47].
The reciprocal relationship between polyphenols and gut microbiota may contribute to host health
benefits. The need to clarify the molecular mechanisms underlying the observed prebiotic enrichment
of beneficial bacteria and antimicrobial activities against gut pathogenic bacteria is apparent [42,48–52].
Commensals residing in the gut may improve health by protecting against gastrointestinal disorders
and pathogens, processing nutrients, reducing serum cholesterol, strengthening intestinal epithelial
tight cell junctions, increasing mucus secretion and modulating intestinal immune response through
cytokine stimulus [53,54]. Furthermore, the gut microbiota biotransforms polyphenols into metabolites
that may have greater biological activity than their precursor structures [42].
3. Metabolism of Phenolics and Microbial/Colonic Metabolic Pathways
Phenolics are mostly found bound to sugars and organic acids that can be grouped into
flavonoids and non-flavonoids. Figures 1 and 2 exhibit the structure of flavonoid-type phenolics
Nutrients 2016, 8, 78 3 of 36
and nonflavonoid-types, respectively. Flavonoid-type phenolics have a primary structure existing
of two benzene rings, A and B, connected through a heterogeneous pyrone C ring. In contrast,
nonflavonoid-type phenolics have a more diverse group of compounds from the simplest C6-C1
benzoic acids to more complicated C6-C2-C6 stilbenes, C6-C3-C3-C6 lignans and gallotannins,
hydrolyzable tannins and ellagitannins [42].
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3.1. Flavonoid-Type Phenolics
3.1.1. Flavonols
Flavonols c tain a 3-hydroxyflavone base (3-hydroxy-2-phenylchromen-4-one) and have
a planar ring system (Figure 1). They are differentiated by their hydroxy modification at
distinct positions of the phenol residue. Foods particularly enriched in flavonols are onions,
broccoli, tea, apples, and red wine [55]. Flavonols are extensively hydrolyzed into their
metabolite-derivative products by gut microbiota at the A and B rings as a result of the
C ring cleavage [56,57]. Accordingly, quercetin provides 2-(3,4-dihydroxyphenyl)acetic acid,
2-(3-hydroxyphenyl)acetic acid, and 3,4-dihydroxybenzoic acid from th B ring, while phloroglucinol,
3-(3,4-dihydroxyphenyl)propionic acid, and 3-(3-hydroxyphenyl)propionic acid are formed from
the A ring. Additional phenolic-metabolites such as 3-methoxy-4-hydroxy-benzoic acid (vanillic
acid), 2,4,6-t ihydr x benzoic acid, 2-(3,4-dihydroxyphenyl)eth nol, 3,4-dihydroxybenzaldehyde,
3-(3,4-dihydroxyphenyl)benzoic acid methyl ester, and 3-(m or p-hydroxyphenyl) propionic acid have
also been recognized. The types of phenolic compounds produced are affected by the mechanism
of B ring hydroxylation. Myricetin trihydroxylation produces 2-(3,5-dihydroxyphenyl)acetic acid,
2-(3-hydroxyph nyl)ac tic acid, and 2-(3,4,5-trihydroxyph nyl)acetic acid. Moreover, kaempferol
(which has a 41-hydroxy-ring B), releases only 2-(4-hydroxyphenyl)acetic acid. In summary, flavonols
are biotransformed by C ring fission, and later by dehydroxylation reactions in the intestine [58].
3.1.2. Flavones and Flavanones
Flavones are flavonoids that have a basic structure consisting of a 2-phenyl-benzo-γ-pyrone
skeleton formed by two phenyl rings (A and B) linked with a heterocyclic pyrone ring (C) (Figure 1).
Flavanones have a 2,3-dihydro-2-phenylchromen-4-one structure. (Figure 1). The pyran rings of
flavanones are nonlinear because they contain saturated C2–C3 bonds. They can form linkages with
estrogen receptors. Furthermore, they do not contain double bonds between C2 andC3, contrary to
isoflavones (Figure 1). Citrus fruits such as lemon, grapefruit, and orange are the most important
dietary sources of flavanones [59].
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In comparison, flavanones have a higher bioavailability compared to flavonols and
flavan-3-ols. This could be explained in part by less degradation by gut microbiota and greater
accessibility for absorption in the intestine. Flavanones occur as glycosides, usually rutinosides
(6-O-α-L-rhamnosyl-D-glucosides) and neohesperidosides (2-O-α-L-rhamnosyl-D-glucosides) at the
seventh position [60]. The degradation pathways of flavanone glycosides such as naringin are
similar to flavonols. The first reaction is a deglycosylation to form naringenin, which then turns
into phloroglucinol and 3-(3,4-dihydroxyphenyl)propionic acid by cleavage of the C ring [58].
3.1.3. Flavone C-Glycosides
Most dietary flavonoids exist in their O-glycosidic forms. However, C-glycosylated flavonoids,
especially flavones, are widespread in a variety of plants [61]. In most cases, flavone O-glycosides are
hydrolyzed by digestive enzymes or degraded by gut bacteria to their aglycones in the intestine to be
reduced and conjugated to form O-glucuronides and O-sulfates in the liver [62,63]. However, flavone
C-monoglucosides exhibit different metabolism pathways compared to flavone C-multiglycosides [63]
(Figure 3). Flavone C-monoglucosides such as orientin, vitexin, homoorientin, and isovitexin are
observed to be poorly absorbed in the gastrointestinal tract of rats and, consequently, were able to
reach the colon [64]. Once in the colon, flavone C-monoglucosides are deglycosylated and degraded
to smaller metabolites, such as phloroglucinol, hydrocaffeic acid, and phloretic acid, by human gut
bacteria, yielding very few metabolites in the urine and blood. Flavone C-multiglycosides are absorbed
intact in the intestine and are minimally changed in the liver. Afterwards, they are returned to the gut
by enterohepatic recirculation [63].
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3.1.4. Isoflavones
Isoflavones have a planar basic ring system with the benzenoid B ring attached to C3,
differentiating it from the other flavonoids. Isoflavonoids are nonsteroidal and estrogen-like due
to their chemical structure. As they are able to bind to estrogen receptors (ERα and ERβ), they are
classified as natural selective estrogen receptor modulators (SERMs) [65–70]. Isoflavones are in the
form of water-soluble glycosides and they cannot be absorbed completely through the enterocyte.
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This is a consequence of their high hydrophilicity and molecular weight. Soy is one of the food products
rich in health-promoting isoflavonoids [65]. Soy products contain 12 identified isoflovone compounds:
three aglycones (genistein, daidzein, glycitein); three glucosides; three acetyl ester glucosides; and three
malonyl ester glucosides. Isoflavones can be biotransformed by β-glucosidase from gut microbiota into
their aglycones for increased bioavailability [70,71]. The aglycones can be both absorbed completely
or metabolized by gut microbiota [72]. Aglycones are also biotransformed into their metabolites,
namely daidzein to O-demethylangolensin (O-DMA) and equol, and genistein to p-ethylphenol
and 4-hydroxyphenyl-2-propionic acid. Equol has higher antioxidant activity than soy isoflavones
due to its nonplanar structure which is more flexible to conformational modification. Though, due
to the absence of specific constituents of the gut microbiota, only about one-third of the human
population can metabolize daidzein into equol. Other observed microbial metabolites of daidzein are
2-dehydro-O-DMA, dihydrodaidzein, tetrahydrodaidzein, 6-hydroxydaidzein, 8-hydroxydaidzein,
and 31-hydroxydaidzein, and 3-(4-hydroxyphenyl)benzopyran-4,7-diol. They are biotransformed
by deglucosylation, reduction, C ring fission, and hydroxylation reactions [65]. Soybean products
contain less than 10% glycitein, but it comprises about half of the isoflavone mass in soy
germ. It is demethoxylated into 6,7,41-trihydroxyisoflavone in vitro by Eubacterium limosum [73].
Metabolites of glycitein have been isolated and characterized as dihydroglycitein, 6-O-methyl-equol,
51-O-methyl-O-desmethylangolensin, and dihydro-6,7,41-trihydroxyisoflavone [74,75].
3.1.5. Flavanols
Simple flavanols such as (+)-catechin (C), (´)-epicatechin (EC), epigallocatechin, their gallate
esters, and polymeric procyanidins from dimers and polymers collectively named condensed tannins
are all classified as flavanols. They are the primary contributors to dietary phenolics and are found
mostly in fruits, tea, wine and chocolate. Similar to flavanones and flavonols, flavanols such as catechin,
epigallocatechin and epicatechin have a B ring attached to C2, but they do not have a carbonyl group
in their C4 position or double bonds between C2 and C3. They are not found in a planar conformation
as flavanones are [42].
Flavanols are promptly metabolized to several O-sulfated, O-glucuronidated, and O-methylated
forms by phase II enzymes [76–79]. The main phenolic-metabolites of catechin and epicatechin are 5-(31,41-
dihydroxyphenyl)-γ-valerolactone, 3-(3-hydroxyphenyl)propionic acid, and 3-hydroxyhippuric acid,
5-(31-hydroxyphenyl)-γ-valerolactone [58,80,81]. Tzounis et al. (2008) found out that when (´)-epicatechin
or (+)-catechin were incubated with intestinal bacteria, 5-(31,41-dihydroxyphenyl)-γ-valerolactone,
5-phenyl-γ-valerolactone, and 3-phenylpropionic acid were formed [48]. For the biotransformation
of these metabolites to proceed, initial conversion to (+)-epicatechin from (+)-catechin is essential.
The metabolites pyrogallol, 3-(3-hydroxyphenyl)propionic acid, 5-(3,4-dihydroxyphenyl)valeric acid,
5-(3-hydroxyphenyl)valeric acid, 3-(3,4-dihydroxyphenyl)propionic acid, 3-(3-methoxyphenyl) valeric
acid, and 2,3-dihydroxyphenoxyl 3-(31,41-dihydroxyphenyl)propionic acid are obtained after in vitro
incubation of epicatechin with the human intestinal microbial community. Dietary condensed
tannins are biotransformed into benzoic, phenylacetic, phenylpropionic, and phenyllactic acid
derivatives, with phloroglucinol, 5-(31-hydroxyphenyl)-γ-valerolactone, and 1-(3-hydroxyphenyl)-3-
(2,4,6-trihydroxyphenyl)propan-2-ol being produced [82]. In another study, condensed tannins
produced 3-(4-hydroxyphenyl)propionic acid, 3-phenylpropionic acid, 2-(3-hydroxyphenyl)acetic acid,
2-(4-hydroxyphenyl)acetic acid, 5-(3-hydroxyphenyl)valeric acid, and 3-(3-hydroxyphenyl)propionic acid
by way of the gut microbiota [80].
The dry weight of green tea consists of 30%–42% catechin. Major catechins are (+)-epigallocatechin
gallate (EGCG), (´)-epigallocatechin (EGC), (´)-epicatechin gallate (ECG), and (´)-epicatechin (EC), in
which EGCG is the most abundant, and may account for 50%–80% of the total catechins in tea [83].
The metabolism of tea catechins by gut microbiota has been studied extensively, demonstrating that the
absorption of catechins in the small intestine is relatively low. As a result, the majority of tea catechins are
biotransformed by gut microbiota, followed by absorption in the bloodstream or excretion in the feces.
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Recently, Takagaki and Nanjo (2013) identified several new metabolites of (+)-C or (´)-EC
biotransformed by rat intestinal microbiota and they revised the suggested metabolic pathway of these
compounds [84]. They have observed four different strains of human intestinal bacteria that have the
ability to biotransform (+)-C and (´)-EC.
Wang et al. (2001) reported that Eubacterium sp. strain SDG-2 biotransformed (+)-C to 1-(31,41-
dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol. However, the bacteria biotransformed
(´)-EC into two compounds, 1-(31,41-dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol and
1-(31-hydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol. Thus, Eubacterium sp. strain SDG-2
has the ability of p-dehydroxylation in the B ring of (´)-EC but not in (+)-C [85].
Recently, Kutschera et al. (2011) revealed that both (+)-C and (´)-EC could be biotransformed
to 1-(31,41-dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol by Eggerthella lenta rK3.
However, the conversion of (+)-C progressed five times faster than that of (´)-EC. Flavonifractor
plautii aK2 further converted 1-(31,41-dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol to
δ-(31,41-dihydroxyphenyl)-γ-valerolactone and δ-(31,41-dihydroxyphenyl)-γ-valeric acid [86].
EGC can be biotransformed by Eubacterium sp. strain SDG-2 into 1-(31,51-dihydroxyphenyl)-3-
(2”,4”,6”-trihydroxyphenyl)propan-2-ol [85]. Moreover, it was observed that 5-(31,41,51-trihydroxyphenyl)-
γ-valerolactone can be formed as an additional major metabolite of EGC [77,78].
Furthermore, it was reported that some phenolic acids were produced such as 3,4-DHPPA,
3-HPPA, 4-HPPA), 3,4-DHPAA, 3-HPAA, 3-HBA, 4-HBA and phloroglucinol [87–89]. Meng et al.
(2002) identified δ-(31,41,51-trihydroxyphenyl)-γ-valerolactone, δ-(31,41-dihydroxyphenyl)-γ-valerolactone,
and δ-(31,51-dihydroxyphenyl)-γ-valerolactone in the urine after EGC consumption [90]. Upon
consumption of 200 mg of pure ECG, δ-(31,41,51-trihydroxyphenyl)-γ-valerolactone, δ-(31,41-
dihydroxyphenyl)-γ-valerolactone, and δ-(31,51-dihydroxyphenyl)-γ-valerolactone were identified in the
urine [90].
Furthermore, (´)-EGCG is the 3-O-gallate product of (´)-EGC, which is the major catechin
derivative found in tea. Van’t Slot and Humpf (2009) reported that (+)-GCG and (´)-EGCG were
degraded by the intestinal microbiota of pig cecum, and biotransformed into (+)-GC and (´)-EGC,
respectively [89]. This degradation is also observed by human and rat intestinal microbiota in in vitro
models of the colon [88,91]. In addition, Takagaki and Nanjo (2010) analyzed the metabolism and
biotransformation of (´)-EGCG by rat intestinal bacteria and proposed three metabolic pathways. In the
first step, (´)-EGCG is hydrolyzed into (´)-EGC and gallic acid. Then, EGC is biotransformed into
1-(31,41,51-trihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol by reductive opening among the first and
second positions of EGC. Subsequently, 1-(31,41,51-trihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol
is biotransformed into 1-(31,51-dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol by dehydroxylation
of 1-(31,41,51-trihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol at the 41 position. Moreover,
as a moor degradation pathway of EGCG metabolism, 5-(31,51-dihydroxyphenyl)-γ-valeric acid is
formed as the main metabolite by ring fission of the phloroglucinol moiety of the metabolite
1-(31,51-dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol. This is the major pathway of EGCG
metabolism. Simultaneously, just after the ring fission, the 5-(31,51-dihydroxyphenyl)-γ-valerolactone metabolite
may be formed according to the lactonization of 5-(31,51-dihydroxyphenyl)-γ-valeric acid and its small
part is biotransformed into 3,5-dihydroxyphenyl-propionic acid. In addition, an insignificant amount
of 41-dehydroxylated metabolite is biotransformed from EGC that is not further metabolized by the gut
microbiota [91].
There are also in vivo studies on the metabolism of EGCG explaining the likely metabolic pathway
as in in vitro studies. In vivo studies on the biotransformation of EGCG after oral administration to rats
revealed that EGCG was relocated into the cecum and large intestine, and then underwent degradation
by intestinal bacteria to 5-(31,51-dihydroxyphenyl)- γ-valerolactone with EGC as an intermediate
product [92,93]. An abundant quantity of 5-(31,51-dihydroxyphenyl)-γ-valerolactone is absorbed in
the body by going through glucuronidation in the intestinal mucosa or liver, transformed to its
glucuronidated metabolites which enter blood circulation. Next they are distributed to various tissues
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and excreted in the urine [90,92,93]. In vivo and in vitro biotransformations of flavan-3-ols are given in
detail with their degradation products in Table 1.
Table 1. In vitro and in vivo biotransformation of flavan-3-ols by gut microbiota.
Compound Metabolite Model (in Vivo/in Vitro)and References
(+)-C or (´)-EC
1-(41-hydroxyphenyl)-3-(2”,4”,6”- trihydroxyphenyl)propan-2-ol Rat in vitro [84]
1-(31-hydroxyphenyl)-3-(2”,4”,6”- trihydroxyphenyl)propan-2-ol Rat in vitro [84]
1-(31,41-dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol Rat in vitro [84]
5-(31-hydroxyphenyl)pentanoic acid Rat in vitro [84]
5-(31,41-dihydroxyphenyl)-4-oxo-valeric acid Rat in vitro [84]
5-(31-hydroxyphenyl)-4-oxo-valeric acid Rat in vitro [84]
5-[(31,41-dihydroxyphenyl)methyl]oxolan-2-one Rat in vitro [84]; Human in vitro [87];Human in vivo [90]
5-[(31-hydroxyphenyl)methyl)oxolan-2-one Rat in vitro [84]; Human in vitro [88]
5-(31,41-dihydroxyphenyl)-pentanoic acid Rat in vitro [84]; Human in vitro [87]
3,4-DHPPA Rat in vitro [84]; Pig in vitro [89]
3-HPPA Rat in vitro [84]; Human in vitro [87]
4-HPAA Pig in vitro [89]
3-HBA Pig in vitro [89]
4-HBA Pig in vitro [89]
Phloroglucinol Pig in vitro [89]
5-[(31,41,51-trihydroxyphenyl)methyl]oxolan-2-one Human in vitro [88]
(+)-GC or (–)EGC
1-(31,51-dihydroxyphenyl)-3-(2”,4”,6”- trihydroxyphenyl)propan-2-ol Human in vitro [87,88]
5-[(31,41,51-trihydroxyphenyl)methyl]oxolan-2-one Human in vitro [87,88]
4-HPAA Human in vitro [87]; Pig in vitro [89]
Phloroglucinol Pig in vitro [89]
3,4-DHPPA Pig in vitro [89]
3-HPPA Pig in vitro [89]
3-HBA Pig in vitro [89]
4-HBA Pig in vitro [89]
(´)-EGC
5-[(31,41,51-trihydroxyphenyl)methyl]oxolan-2-one Human in vivo [90]
5-[(31,41-dihydroxyphenyl)methyl]oxolan-2-one Human in vivo [90]
5-[(31,51-dihydroxyphenyl)methyl)]oxolan-2-one Human in vivo [90]
(´)-ECG
EC Rat in vivo [92,93]
Gallic acid Rat in vivo [92,93]
Pyrogallol Rat in vivo [92,93]
1-(31,41-dihydroxyphenyl)-3-(2”,4”,6”- trihydroxyphenyl)propan-2-ol Rat in vivo [92,93]
5-[(31,41-dihydroxyphenyl)methyl]oxolan-2-one Rat in vivo [92,93]
5-[(31-hydroxyphenyl)methyl)]oxolan-2-one Rat in vivo [92,93]
5-(31,41-dihydroxyphenyl)pentanoic acid Rat in vivo [92,93]
3-HPPA Rat in vivo [92,93]
(E)-3-(3-hydroxyphenyl)-acrylic acid Rat in vivo [92,93]
EGC Rat in vivo [92,93]
(+)-GCG or
(´)-EGCG
EGC Rat in vitro [91]; Human in vitro [87,88];
Pig in vitro [89]
Gallic acid Rat in vitro [91]; Human in vitro [87,88];Pig in vitro [89]
5-[(31,41,51-trihydroxyphenyl)methyl]oxolan-2-one Rat in vitro [91]; Pig in vitro [89]
1-(31,41,51-trihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol Rat in vitro [91]
1-(31,51-dihydroxyphenyl)-3-(2”,4”,6”- trihydroxyphenyl)propan-2-ol Rat in vitro [91]
5-(31,51,- dihydroxyphenyl) pentanoic acid Rat in vitro [91]
5-(31,41,51-trihydroxyphenyl) pentanoic acid Rat in vitro [91]
5-(31-hydroxyphenyl)-pentanoic acid Rat in vitro [91]
5-[(31,51-dihydroxyphenyl)methyl)]oxolan-2-one Rat in vitro [91]
3,5-DHPPA Rat in vitro [91]
5-[(31,41,51-trihydroxyphenyl)methyl]oxolan-2-one Human in vitro [87]
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Table 1. Cont.
Compound Metabolite Model (in Vivo/in Vitro)and References
(+)-GCG or
(´)-EGCG
Pyrogallol Human in vitro [87]
Pyrocatechol Human in vitro [87]
4-HPAA Human in vitro [87]
(´)-EGCG
EGC Rat in vivo [92,93]
Gallic acid Rat in vivo [92,93]
1-(31,41,51-trihydroxyphenyl)-3-(2”,4”,6”-
trihydroxyphenyl)propan-2-ol
Rat in vivo [92,93]
1-(31,51-dihydroxyphenyl)-3-(2”,4”,6”-trihydroxyphenyl)propan-2-ol Rat in vivo [92,93]
5-[(31,41,51-trihydroxyphenyl)methyl]oxolan-2-one Rat in vivo [92,93]
5-[(31,51-dihydroxyphenyl)methyl)]oxolan-2-one Rat in vivo [92,93]
5-[(31,41-dihydroxyphenyl)methyl]oxolan-2-one Rat in vivo [92,93]
Abbreviations: 3,4-DHPPA, 3,4-dihydroxyphenylpropionic acid; 3-HPPA, 3-hydroxyphenylpropionic acid;
4-HPPA, 4-hydroxyphenylpropionic acid; 3-HBA, 3-hydroxybenzoic acid; 4-HBA, 4-hydroxybenzoic
acid; 3,4-DHPAA, 3,4-dihydroxyphenylacetic acid; 3-HPAA, 3-hydroxyphenylacetic acid; 4-HPAA,
4-hydroxyphenylacetic acid.
3.1.6. Anthocyanins
Anthocyanins belong to a large group of secondary plant metabolites collectively known
as flavonoids [94]. They are responsible for the red and blue pigmentation of many fruits and
vegetables [95]. The health benefits of anthocyanins have been demonstrated in several in vivo and
in vitro studies [96–98]. However, the low bioavailability of anthocyanins is a clear obstacle in achieving
desired beneficial effects [99].
Several studies on the intestinal absorption of anthocyanins have been reported. The anthocyanins
delphinidin 3-O-rutinoside, cyanidin 3-O-rutinoside, delphinidin 3-O-glucoside, and cyanidin
3-O-glucoside were found to be directly absorbed and excreted as the glycosylated forms in both rats
and human subjects [100]. A number of studies showed that the proportion of total anthocyanins
absorbed and subsequently excreted in urine was far below 1% [101]. By collecting ileostomy effluent
after the consumption of anthocyanin-rich blueberries, Kahle et al. (2006) determined that up to
85% of blueberry anthocyanins reach the colon under physiological conditions [102]. However,
about 69% of the anthocyanins disappeared from the gastrointestinal tract within 4 h after food
ingestion [103,104]. As demonstrated by in vitro fermentation of anthocyanins seeded by a fecal
community obtained from rats, cyanidin-3-glucoside and cyanidin-3-rutinoside extracted from wild
mulberry were completely degraded within 10 hours [105]. It is thus likely that intestinal microbiota
contribute to the biotransformation and the metabolism of anthocyanins [106].
Fleschhut et al. (2006) incubated an anthocyanin-rich extract from red radish with human fecal
suspension in vitro and demonstrated that the first step of the bacterial hydrolysis of anthocyanins (i.e.,
monoglucosides, diglucosides as well as acylated anthocyanins) involves the cleavage of the sugar
moiety leading to the formation of the anthocyanin aglycon. The activities of two bacterial enzymes
in particular, α,L-rhamnosidase and β,D-glucosidase, may be responsible for the deglycosylation of
anthocyanins [94]. Due to the high instability of the liberated aglycones at the pH of various locations
in the intestine, they might spontaneously change to form quinoid bases, which further break down
into a phenolic acid and an aldehyde via an α-diketone intermediate (Figure 4). Therefore, the major
degradatory pathway of this process is the formation of the phenolic acid descending from the B ring
of the anthocyanin skeleton (Table 2) [94,95].
Many studies have shown that protocatechuic acid is one of the most likely major degradation products
of anthocyanins. In a human study, Vitaglione et al. (2007) identified that protocatechuic acid was the major
metabolite of cyanidin-O-glucosides, accounting for almost 73% of ingested cyanidin-O-glucosides [101].
After consumption of black raspberries in a porcine model, the phenolic acid profile in the gastrointestinal
tract indicated that protocatechuic acid was the major metabolic derivative, followed by p-coumaric acid,
caffeic acid, ferulic acid and 3-hydroxybenzoic acid [107]. In addition, a high level of protocatechuic
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acid was also identified in rat plasma after the oral intake of cyanidin 3-O-β-D-glucoside [108]. Cyanidin
3-O-β-D-glucoside was reported to metabolize to protocatechuic acid via cyanidine when incubated with
fecal microbiota in an in vitro model. This resulted in a more potent anti-scratching behavioral effect than the
parent cyanidin 3-O-β-D-glucoside in mice, thus suggesting the biological activity of anthocyanins in vivo
may increase due to their metabolites, such as phenolic acids [109].
Table 2. The expected B ring fragments for the common anthocyanidins. Reproduced from the original
source [110].
Anthocyanidin Initial B-Ring Fragmentation Product
Pelargonidin 4-Hydroxybenzoic acid
Cyanidin Protocatechuic acid
Delphinidin Gallic acid
Peonidin Vanillic acid
Petunidin 3-Methoxy-4,5-dihydroxybenzoic acid
Malvidin Syringic acid
Nutrients 2016, 8, 78 10/35 
glucoside in mice, thus suggesting the biological activity of anthocyanins in vivo may increase due to 
their metabolites, such as phenolic acids [109]. 
Table 2. The expected B ring fragments for the common anthocyanidins. Reproduced from the 
original source [110]. 
Anthocyanidin Initial B-Ring Fragmentation Product 
Pelargonidin 4-Hydroxybenzoic acid 
Cyanidin Protocatechuic acid 
Delphinidin Gallic acid 
Peonidin Vanillic acid 
Petunidin 3-Methoxy-4,5-dihydroxybenzoic acid 
Malvidin Syringic acid 
 
Figure 4. pH-dependent structural changes and degradation of cyanidin-3-glucoside. Reproduced 
from the original source [94]. 
3.2. Nonflavonoid-Type Phenolics 
3.2.1. Phenolic Acids 
Figure 4. pH-dependent structural changes and degradation of cyanidin-3-glucoside. Reproduced
from the original source [94].
3.2. Nonflavonoid-Type Phenolics
3.2.1. Phenolic Acids
Phenolic acids are found in many foods, and in high concentrations in whole grains, wine and
berries. Cereals contain mostly the hydroxycinnamate ferulic acid as a phenolic acid. It is found bound
to arabinoxylans by ester bonds in rye. Therefore, esterases (e.g., cinnamoyl estarase) are required
during digestion or by the gut microbiota to improve its bioaccessibility [111,112]. As a result of this
hydrolysis, unbound phenolic acids can be absorbed through the gastrointestinal barrier and enter
peripheral circulation [113].
Moreover, in vitro hydroxycinnamic acid conversions by gut microbiota can be observed. In a
study conducted by Gonthier and colleagues (2006), caffeic acid and its esters, caftaric acid and
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chlorogenic acid, were used as a substrate in a human colon model and phenolic acids were transformed
into 3-(31-hydroxyphenyl)propionic acid and minor quantities of benzoic acid. The side-chain
shortening of phenylpropionic acid arises through β-oxidation [114]. Caffeic acid can also be
decarboxylated and metabolized into 4-ethylcatechol by gut microbiota [115].
Ferulic acid dimers are other important phenolic acids released from cereals [116]. Two ferulic
acids can be bound to each other either through 8-O-4- or 5-5-linkages. In the study of Braune et al.
(2009), dehydrodiferulic acid 8-O-4- and 5-5-derivatives were incubated with human fecal microbiota.
The 8-O-4 derivative was shown to degrade temporarily to monomeric ferulic acid, which was
then biotransformed into 3-(31,41-dihydroxyphenyl)propionic acid, 31,41-dihydroxyphenyl acetic acid,
3-phenylpropionic acid, and benzoic acid. An alternative pathway to benzoic acid is related to the
metabolism of 3-(41-hydroxy-31-methoxyphenyl)pyruvic acid. Contrarily, the 5-5-diferulate derivatives
were exposed only to demethylation and/or side-chain reductions [117].
3.2.2. Stilbenes
Stilbenoids are very typical polyphenols in our diets, which mainly present in red grapes, wines,
cranberries, strawberries, and peanuts [118,119]. Resveratrol and its derivatives are the most important
dietary stilbenoids associated with many benefits for human health [120–122]. trans-Resveratrol
is metabolized by human gut microbiota to dihydroresveratrol, 3,41-dihydroxy-trans-stilbene and
3,41-dihydroxybibenzyl (lunularin) in vivo [123]. trans-Piceid, the 3-O-β-D-glucoside of resveratrol, is
metabolized to resveratrol, dihydropiceid and dihydroresveratrol by gut microbiota [124].
3.2.3. Lignans
Lignans consist of pinoresinol, matairesinol, secoisolariciresinol, isolariciresinol, syringaresinol
and lariciresinol diphenolic compounds with a 1,4-diarylbutane structure [125]. They are mostly
found in fruits and vegetables, tea, cereal products, and coffee [126]. If consumed, they are potentially
metabolized by microbial processes [2,127–129]. Lignans are considered phytoestrogens because of
their estrogen agonist or antagonist properties [2]. The biological activity of lignans is associated with
their activation into enterolactone and enterodiol, which are mammalian phytoestrogens [130–132].
The bioavailability of lignans is directly associated with intestinal bacterial metabolism [128]. These
biotransformation reactions require demethylation and dehydroxylation [133].
3.3. Limitations for the Studies on Metabolism of Phenolics and Microbial/Colonic Metabolic Pathways
By reviewing the latest studies, it can be concluded that phenolic compounds are biotransformed
by gut microbiota, generating intermediate and final related metabolites that could be present in
the digesta in higher concentrations than their precursors. These phenolic metabolites do not share
the same bioavailability and health effects with their parent compounds. In this context, there is an
inherent limitation in the studies focused on analyzing the parent compounds in food to correctly
estimate the phenomena occurring in the colon. Studies should focus on identifying whether the health
benefits are associated with the parent compounds or their phenolic metabolites.
There are also many studies in the literature that observe the biotransformation of phenolic
compounds in a food matrix, but studies using pure phenolic compounds are limited. Indeed, food
has a complex matrix, and it is difficult to understand the phenolic–gut microbiota interactions directly,
as some interactions with other food components might occur. It is important to understand the effect
of gut microbiota on pure, individual phenolic compounds.
Another limitation is that it is not clear which intestinal bacteria have an effect on which phenolic
compounds. Therefore, it is important to investigate the specific intestinal bacteria implicated in the
metabolism of dietary polyphenols.
Phenolic compounds represent a large group, containing many sub-classes, as described.
Although they have similar characteristics, there are important differences in their chemical structures,
the number of functional groups, and the combination of different moieties, which lead to different
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functional activities. Despite the information obtained and published over recent years, microbial
mechanisms of action on each phenolic compound and their metabolites remain unclear, and further
research is needed to ascertain causal relationships.
4. Bioactivity and Bioavailability of Polyphenols are Affected by Gut Microbiota
Bioaccessibility is an important factor in determining bioavailability, and is a prerequisite for intestinal
absorption. The process involves the release of compounds from an encapsulating food matrix that can be
solubilized during digestion, and is potentially available for further absorption [7]. Polyphenols exert their
functional influence dependent on intestinal absorption. Some polyphenols are found more distributed
in nature but may not be bioavailable. The amount of bioaccessible phenolic compounds may differ
significantly. Some phenolic compounds may be released and absorbed in small amounts, similar to
carotenoids [134]. Some polyphenols, such as anthocyanins, might be degraded before reaching their
site of absorption that results in bioaccessibility levels below 10% [135]. Therefore, a comprehensive
understanding of the reactions that occur during digestion is essential to understand and estimate the
bioaccessibility of these polyphenols.
Polyphenol structure is an important factor influencing bioavailability. Polyphenols that are
most commonly found in dietary components are glycosides (e.g., flavonols, flavones, flavanones,
isoflavones and anthocyanins). Less endemic oligomers (proanthocyanidins) are not absorbed by
intestinal mucosa [136]. In the intestinal mucosa, only aglycones and some glucosides can be
absorbed [137]. Thus, human digestive and microbial enzymes help to release native polyphenols
from the food matrix, which is an essential mechanism for them to pass through the intestinal
barrier [138,139]. The released aglycones and polyphenol monomers can be transported through
passive diffusion and membrane permeases into enterohepatic circulation [136]. There they will be
conjugated and returned to the small intestine, along with bile during passage into the liver, mainly
by glucuronidation and sulphation reactions. Unabsorbed polyphenols in the small intestine are
deconjugated by microbial glucuronidases and sulphatases in the colon, permitting the reuptake of
aglycones [140,141]. In addition, intestinal microbiota are able to degrade aglycones and release simple
aromatic compounds, including hydroxyphenylacetic acids from flavonols, hydroxyphenyl-propionic
acids from flavones and flavanones and phenylvalerolactones and hydroxyphenylpropionic acids from
flavanols. This renders them available for subsequent absorption and conjugation [139].
The enveloping food matrix that surrounds polyphenols influences the bioavailability of the
molecules. Polyphenols that are integrated into a cellular structure can be released and absorbed in
the intestinal mucosa during chewing and food digestion [140,141]. While some foods are consumed
unprocessed, many food products require a degree of processing which may alter the bioavailability
of phenolic compounds. For example, orange juice processing precipitates flavanones through
interactions with pectins and other orange macromolecules, leading to lower bioavailability than
the unprocessed phenolic compounds [142]. Furthermore, almond skin polyphenols have lower
bioavailability after industrial bleaching [143].
Polyphenols also interact with other nutrients or ingredients that influence their bioavailability.
Protein-phenolic interactions generally decrease bioavailability [144], as do associations with dietary
fiber [145]. However, lipids seem to enhance the availability of phenolic compounds [146].
Two-way, reciprocal interactions of gut microbiota and phenolic compounds have an important
impact on the bioavailability of phenolic compounds and human health. Gut microbiota plays an
important role in harvesting nutrients from the diet [147]. Phenolic compounds that are not readily
absorbed in the small intestine serve as growth substrates for the members of the gut microbial community,
which in turn modify the bioavailability and nutritional properties of these compounds [147]. Phenol
Explorer Database Release 2.0 [148] is a useful and capable resource, as it allows rapid retrieval of data
on the biotransformations and pharmacokinetics of dietary polyphenols. Pharmacokinetic data on 380
metabolites identified in biofluids after the consumption of polyphenol-rich sources are presented in the
database. These data have been extracted from 236 publications, and originate from 221 intervention
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studies in human subjects and experimental animals. This database is important for polyphenol scientists
as bioactivities and health effects of polyphenols are dependent on the nature and concentrations of
metabolites reaching the target tissues [148]. Higher bioavailability of phenolic compounds, and the
resultant beneficial health effects as determined by the consumption of whole grains, vegetables and
fruits, can be related to the end-products of microbial metabolism forming short-chain fatty acids such as
butyrate, and phenolic acids such as protocatechuic acid [149–152].
In a very recent study by Esposito et al. (2015), the gastrointestinal distribution of black currant
anthocyanins and their phenolic acid metabolites were examined in lean and diet-induced obese mice with
healthy and antibiotic-disrupted microbiomes. Daily consumption of low-fat or high-fat diet supplemented
with 1% black currant powdered extract (32% anthocyanins) for eight weeks reduced body weight gain
and improved glucose metabolism only in mice with the intact gut microbiome. Administration of
antibiotic cocktail resulted in a 16- to 25-fold increase (p < 0.001) in the anthocyanin content of feces, and
cyanidin-based anthocyanins showed the largest increase in fecal content upon disruption of the gut
microbiome, indicating their high susceptibility to microbial degradation in the gut. A three-fold increase
in gallic acid over protocatechuic acid was observed in the jejunum of both intact and antibiotic-treated
animals, suggesting that this effect was likely independent of gut microbiome status. As a result of this
study, it can be concluded that the gut microbiome is necessary for the protective effect of black currant
anthocyanins against obesity and the associated insulin resistance [153].
The bioavailability of red raspberry anthocyanins and ellagitannins was studied by Ludwig et al.
(2015), considering their biotransformation by gut microbiota. They fed volunteers with red raspberries,
containing ellagitannins and cyanidin-based anthocyanins, and analyzed metabolites appearing in
plasma and urine by UHPLC-MS. They have indicated that metabolism of anthocyanins appears
to start in the upper gastrointestinal tract, possibly pH-initiated, with 41-hydroxyhippuric acid and
ferulic acid derivatives circulating in plasma with a Cmax of 1–1.5 h after consumption of raspberries.
Furthermore, formation of these compounds was associated exclusively with the action of the colonic
microflora. Ellagitannins pass from the small to the large intestine, where the colonic microbiota
mediates the conversion to urolithins A and B. These compounds appeared in plasma and were excreted
almost exclusively as sulfate and glucuronide metabolites. The urolithin metabolites persisted in the
circulatory system and were excreted in urine for much longer periods of time than the anthocyanin
metabolites, although their overall urinary recovery was lower, at 7.0% of intake. Events that originate
in the proximal and distal gastrointestinal tract, and are succeeded by phase II metabolism, play an
important role in the bioavailability of both anthocyanins and ellagitannins. Their metabolites, which
appear in the circulatory system, are key to elucidating the mode, or modes, of action underlying
the protective effects of these compounds on human health [154]. Similar results were obtained in
previous bioavailability studies with anthocyanins and ellagitannins [155–158].
An important study explaining the effect of altered gut microbiota on the bioavailability of
phenolics, performed by Dudonne et al. (2015), investigated the bioavailability of cranberry phenolics
after oral administration of a cranberry extract (CE) to high-fat, high-sucrose (HFHS)-fed mice. Their
work explored the possible modulation of gut microbiota composition following a co-supplementation
with spores of Bacillus subtilis CU1 probiotic (CE/P). They extracted and characterized phenolic
metabolites from plasma using µSPE-UHPLC-MS/MS, and a metagenomic analysis was performed on
feces to assess gut bacterial composition. Twenty-two circulating metabolites were identified, mainly
microbial degradation products of native cranberry phenolic compounds. Plasma concentration of
three microbial metabolites was significantly increased with the CE/P co-treatment: p-coumaric acid,
m-coumaric acid and p-hydroxybenzoic acid (+53%, +103% and +70%, respectively). They reported
significant differences in the proportion of Barnesiella and Oscillibacter genera in CE/P-treated mice in
comparison with control animals. This study pointed out that altered gut microbiota has a significant
effect on the degradation and bioavailability of phenolic compounds in mice [159].
In contrast, it has been proposed that high concentrations of phenolic compounds could exert
potential health benefits within the gastrointestinal tract [160]. Choy et al. (2013) studied the
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bioavailability of proanthocyanidins after ingestion of grape seed extract. Their findings indicate that
ingested polymeric proanthocyanidins were present in the colon as the intact parent compounds and
thus may contribute to the health of the gastrointestinal tract [161]. The same finding was reported
previously, as in studies by He et al. (2005) that showed that high levels of anthocyanins in fecal content
may play an important role in colonic health [162].
In summary, recent literature demonstrates that the mutual relationship between gut microbiota
and phenolic compounds increases the bioavailability of phenolics and provides increased health
benefits. Phenolic compounds can alter the gut microbiota community, resulting in a greater
abundance of beneficial microbes, and a consequent increase in bioavailability. At the same time,
phenolic compounds are biotransformed into their smaller metabolites by gut microbiota, which also
contributes to increased bioavailability. The persistence of larger, intact phenolic compounds such as
proanthocyanidins in the colon would allow these compounds to exert local beneficial biological actions,
particularly on colonic epithelial cells, resulting in protective effects against inflammation-mediated
diseases including colorectal cancer.
5. Polyphenols Modulate the Gut Microbiota Composition
Several phenolic compounds have been recognized as potential antimicrobial agents with
bacteriostatic or bactericidal actions. In addition, they also inhibit bacterial infections of intestinal and
urinary tract epithelia. Selma et al. (2009) reviewed the influence of human intestinal bacteria on health
and the incidence of disease [42]. Gut health is mainly determined by the complex interactions between
host and gastrointestinal microbiota. Beneficial bacteria such as Bifidobaterium spp. and Lactobacillus spp.
have been observed to contribute to human health at different levels [163]. They enhance gut barrier
function, stimulate the host immune system, prevent diarrhea or allergies, contribute to activation
of provitamins, and modulate lipid metabolism [163,164]. However, there are other bacterial species
associated with negative implications, such as Clostridium difficile, which has been associated with
inflammatory bowel disease [165]. Therefore, it is of crucial importance to understand the inhibitory
or stimulatory effect of phenolic compounds on beneficial or pathogenic bacteria, and their ratio in the
gut. The influence of phenolic compounds on gut microbiota is provided in detail (Table 3).
5.1. Flavonoid-Type Phenolics
5.1.1. Flavonols
Duda Chodak (2012) studied the impact of flavonols (i.e., quercetin and rutin) on specific intestinal
microbial species. In this study, six bacteria species (Bacteroides galacturonicus, Lactobacillus sp.,
Enterococcus caccae, Bifidobacterium catenulatum, Ruminococcus gauvreauii, and Escherichia coli) were
inoculated with pure flavonols at final concentrations of 4, 20, and 50 µg/mL of quercetin and at 20,
100, and 250 µg/mL of rutin. Interestingly, quercetin showed a dose-dependent inhibitory effect on
the growth of all analyzed bacterial species, whereas this effect was weaker for rutin [166].
Etxeberria et al. (2015) investigated whether quercetin administration could reverse the gut
microbiota community attributable to a high-fat and high-carbohydrate diet and thereby impact
health. Quercetin supplementation resulted in an altered composition of gut microbiota at different
taxonomic levels, including the relative Firmicutes: Bacteroidetes ratio and inhibiting the growth of
bacterial species associated with diet-induced obesity such as Erysipelotrichaceae, Bacillus spp., and
Eubacterium cylindroides [167].
In an in vitro study conducted by Kawabata and colleagues (2013), Bifidobacterium adolescentis,
a commensal often isolated from the human intestine was incubated with different flavonols (i.e.,
quercetin, myricetin, galangin, kaempferol, and fisetin) to evaluate the effects of flavonols on the
growth of B. adolescentis. Although galangin inhibited the growth of B. adolescentis by 30%–70%
when co-cultured for 1–6 h, quercetin and fisetin showed no or little effect on the growth rate (20%
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inhibition at 6 h). Their study revealed that the tested flavonols, except for galangin, have no or weak
anti-bacterial activity against B. adolescentis [168].
5.1.2. Flavones and Flavanones
In a study by Parkar et al. (2008), many different polyphenols were demonstrated to influence the
growth of human gut bacteria and their adhesion to enterocytes. Accordingly, naringenin promoted the
growth of Lactobacillus rhamnosus, commensal Escherichia coli, along with two pathogens, Staphylococcus
aureus and Salmonella typhimurium. In general, the Gram-positive enteropathogen S. aureus was the
most sensitive to naringenin, while the Gram-negative pathogen S. typhimurium and the commensal
organism E. coli were likely to be similar in their sensitivity to naringenin [169].
Moreover, Duda Chodak (2012) also studied the impact of naringenin and hesperetin on
six bacteria species (Bacteroides galacturonicus, Lactobacillus sp., Enterococcus caccae, Bifidobacterium
catenulatum, Ruminococcus gauvreauii, and Escherichia coli) and found out that they inhibited the growth
of almost all analyzed bacteria (MIC ě 250 µg/mL) [166].
5.1.3. Isoflavones
Isoflavones are transformed by gut microbiota, although there are few studies regarding the
effect of isoflavone supplementation on gut microbiota composition. Parkar et al. (2008) investigated
isoflavones (e.g., daidzein and genistein) on the growth of microbiota. As such, isoflavones induced a
decrease in bacterial growth [168]. In another study by Clavel et al. (2005), postmenopausal women
were supplemented with isoflavones (100 mg/day) for two months. As a result of the supplementation,
it was observed that isoflavones changed predominant bacterial populations with enrichment of
the Clostridium coccoides-Eubacterium rectale (Erec) cluster, Faecalibacterium prasnutzii subgroup, and
Lactobacillus-Enterococcus group. The increased concentrations of the Erec cluster were proposed to be
related with an intestinal metabolite from a daidzein named equol [170].
5.1.4. Flavanols
Tzosunis et al. (2008) investigated the reciprocal metabolic interactions between gut microbiota
and (´)-epicatechin and (+)-catechin using a pH-controlled, stirred, batch-culture fermentation system
to model the distal colon. Interestingly, (+)-catechin influenced the growth of specific bacterial
populations, including a statistically significant increase in the Clostridium coccoides–Eubacterium rectale
group, Bifidobacterium spp. and Escherichia coli, as well as inhibiting the growth of the Clostridium
histolyticum group. In contrast, (´)-epicatechin proved to be less active, only significantly increasing
the C. coccoides–Eubacterium rectale group. These potential prebiotic effects for both (+)-catechin and
(´)-epicatechin were most notable at a low concentration of 150 mg/L. As both (´)-epicatechin and
(+)-catechin were converted to the same metabolites, the more dramatic change in the growth of
distinct commensal populations produced by (+)-catechin incubation may be linked to the bacterial
conversion of (+)-catechin to (´)-epicatechin. In summary, these data suggest that the consumption of
flavanol-rich foods may support gut health through their ability to exert prebiotic actions [171].
In the study of Cueva et al. (2013), two flavan-3-ol fractions were used to investigate the in vitro
fermentation with bacterial populations monitored by fluorescent in situ hybridization correlated
with the appearance of phenolic metabolites. Both flavanol fractions promoted the growth of
Lactobacillus/Enterococcus and decreased the C. histolyticum group during fermentation. Together, these
data suggest that flavan-3-ol modulates microbiota composition and inherent catabolic activity, inducing
changes that could affect the bioavailability and potential bioactivity of these compounds [172].
In an in vivo study done by Choy et al. (2014), six crossbred female pigs were fed with a diet
containing grape seed extract for six days. DNA was extracted from pig fecal samples and the V3/V4
region of the 16S rRNA gene was sequenced using an Illumina MiSeq. The results indicated that
the diet containing grape seed extract resulted in modulation of the gut microbiome, dramatically
increasing Lachnospiraceae, Clostridiales, Lactobacillus and Ruminococcaceae. They have reported that the
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relationship between dietary proanthocyanidins and colon health may be attributed to the modulation
of gut microbiota [173].
5.1.5. Anthocyanins
Hidalgo et al. (2012) investigated the bacterial metabolism of malvidin-3-glucoside, gallic acid
and a mixture of anthocyanins using an in vitro model of the human gut. The anthocyanins universally
enhanced the growth of Bifidobacterium spp. and Lactobacillus-Enterococcus spp. significantly. This
suggests that anthocyanins and their metabolites may positively select for beneficial members of
the gut microbial community. Interestingly, malvidin-3-glucoside mixed with other anthocyanins
exhibited a synergistic effect in promoting beneficial microbes [174].
Ultimately, there are very few in vitro, animal, and human intervention studies of anthocyanin
interactions with gut microbiota. Thus, it is difficult to compare results and synthesize a conclusion,
due in part to the varying techniques used to study microbiota, the different sources of anthocyanins,
and study designs. Clearly, further research is necessary to clarify if anthocyanins have a direct or
indirect effect on beneficial/pathogenic bacteria growth.
5.2. Nonflavonoid-Type Phenolics
5.2.1. Phenolic Acids
In the study performed by Hidalgo et al. (2012), in vitro incubation of gallic acid in a fecal slurry
reduced a group of potentially harmful bacteria such as Clostridium histolyticum without any negative
effects on beneficial bacteria. In addition, it significantly reduced Bacteroides spp. growth and enhanced
both the total bacterial number and the abundance of Atopobium spp. [174].
In another study, the influence of hydroxycinnamic acids such as caffeic acid, chlorogenic acid,
o-coumaric acid, p-coumaric acid on the growth of a probiotic microbe (Lactobacillus rhamnosus), a
commensal (Escherichia coli) and two pathogenic bacteria (Staphylococcus aureus, Salmonella typhimurium)
was investigated. They compared the MIC values of all polyphenols tested and observed that flavonols,
isoflavones and glycosides have a low antibacterial activity, while phenolic acids were found to be
at an intermediate level. On the other hand, the flavanone and flavanol tested had high antibacterial
activity [169].
5.2.2. Hydrolyzable Tannins (Ellagitannins)
Ellagitannins are hydrolyzable tannins that are hydrolyzed in vivo to release ellagic acid. They
produce urolithin when they are metabolized by the gut microbiota. The effect of these tannins on the
growth of intestinal bacteria is inadequately characterized, and generally their antimicrobial potential
has been assessed in vitro.
In an in vitro study conducted by Bialonska et al. (2009), the effect of a commercial pomegranate
extract at a concentration of 0.01% as well as the effect of its main constituents (0.05%) on the growth
of several species of human gut bacteria using a liquid culturing method was investigated. As a result
of this study, it was observed that pomegranate byproducts and punicalagins inhibited the growth of
pathogenic Clostridia and Staphylococcus aureus. Interestingly, probiotic Lactobacilli and Bifidobacteria
were generally not affected by ellagitannins [175]. It is important to note that Bialonska et al. (2010)
intended to prove whether this trend was maintained using a fermentation batch-culture system
inoculated with fecal samples from healthy individuals, which better simulates conditions from the
colonic region. In this experiment, pomegranate extract was able to produce an incremental increase
on total bacterial number, enhancing the growth of Bifidobacterium spp., Lactobacillus and Enterococcus
groups, while no effect was observed for the C. histolyticum group [176].
In the study of Larrosa et al. (2010), the ellagitanins of pomegranate and their main microbiota-
derived metabolite urolithin A have also been identified to be responsible for changes in intestinal
microbiota in rats with an increase of Bifidobacterium and Lactobacillus levels [177].
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A different in vivo study, Li et al. (2015) had 20 healthy volunteers consume 1000 mg of
pomegranate extract (POM) for four weeks. Changes in gut microbiota composition were monitored.
Three distinct groups were established according to the urinary and fecal content of the POM metabolite
urolithin A (UA). These groups were classified as (1) individuals with no baseline UA presence but
induction of UA formation by POM extract consumption (n = 9); (2) baseline UA formation which
was enhanced by POM extract consumption (n = 5); and (3) no baseline UA production, which was
not inducible (n = 6). According to the results, Actinobacteria was increased and Firmicutes decreased
significantly in individuals forming UA (producers). Additionally, Verrucomicrobia (Akkermansia
muciniphila) was 33- and 47-fold higher in stool samples of UA producers compared to non-producers
at baseline and after four weeks, respectively. In UA producers, the genera Butyrivibrio, Enterobacter,
Escherichia, Lactobacillus, Prevotella, Serratia and Veillonella increased in abundance, and Collinsella
decreased significantly at week 4 compared to the baseline. The consumption of POM extract resulted
in the formation of its metabolites in some but not all participants. POM extract consumption may
induce health benefits secondary to changes in the microbiota [178].
5.2.3. Stilbenes
The antimicrobial effects of resveratrol (3,5,41-trihydroxy-trans-stilbene) against several pathogenic
and beneficial bacteria have been reported. In the in vivo study of Larrosa et al. (2009), rats were fed
with 1 mg of resveratrol/kg/day (a human-equivalent dose) for 25 days, and in the last five days,
5% dextran sulfate sodium (DSS) was administered to induce colitis. Effects on colon tissue damage,
gut microbiota, reactive oxygen species, inflammatory markers and nitric oxide production as well
as gene expression profile with microarrays were evaluated. Resveratrol increased lactobacilli and
bifidobacteria as well as diminished the increase of enterobacteria upon DSS treatment [179].
In another study of Qiao et al. (2014), mice were supplemented by resveratrol (200 mg per kg
per day) and the changes in gut microbiota were monitored and quantified by fluorescence in situ
hybridization and flow cytometry methods. Results of this study showed that resveratrol ameliorates
the dysbiosis in the gut microbiota induced by the high-fat diet, specific effects including an increase
in the Bacteroidetes-to-Firmicutes ratio, significant inhibition of the growth of Enterococcus faecalis, and
increased growth of Lactobacillus and Bifidobacterium [180].
Etxeberria et al. (2015) determined whether trans-resveratrol administration could affect gut
microbiota modulation produced by a high-fat sucrose (HFS) diet, thereby improving gut health.
Trans-resveratrol supplementation significantly reduced the mean relative abundance of different
Clostridia species such as Clostridium aldenense (´93.1%), Clostridium hathewayi (´73.2%), Clostridium sp.
C9 (´76.3%) and Clostridium sp. MLG661 (´53.7%). This data is in opposition to the mean relative
abundance of Clostridium sp. XB90 (266.6%) which was notably enhanced when compared to the
HFS-diet-fed control rats. Additionally, the percentage of change in the mean relative abundance of
Gracilibacter thermotolerans (´57.7%) and Parabacteroides distasonis (´77.4%) was negatively affected
by trans-resveratrol in comparison to that detected in the HFS-diet-fed control group. Moreover,
trans-resveratrol supplementation produced a statistically significant inhibition in the Graciibacteraceae
family (´57.7%) compared to the HFS-diet-fed control rats. As a result of this study, it is stated that
trans-resveratrol supplementation alone or in combination with quercetin almost modified the profile
of gut bacteria, but instead acted at the intestinal level [167].
5.2.4. Lignans
In the study of Niemi et al. (2013), a lignin-rich fraction originating from brewers’ spent grain did
not suppress the conversion activity of gut microbiota in an in vitro colon metabolic model, nor did
it inhibit the growth of beneficial gut bacteria, lactobacilli and bifidobacteria [180]. Moreover, some
component in the protease-alkaline extracted fraction enabled the growth of bifidobacteria for a longer
time than glucose [181].
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Table 3. Influence of phenolic compounds in gut microbiota composition.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
IN VITRO CELL CULTURE STUDIES
Flavonols
Quercetin
Bacteroides galacturonicus (´) In vitro Counting on culture medium 24 h 4, 20 or 50 µg/mL [166]
Lactobacillus sp. (´)
Enterococcus caccae (´)
Bifidobacterium catenulatum (´)
Ruminococcus gauvreauii (´)
Escherichia coli (´)
Rutin 20, 100 or 250 µg/mL
Bacteroides galacturonicus, NS
Lactobacillus sp. (+)
Enterococcus caccae NS
Bifidobacterium catenulatum (´)
Ruminococcus gauvreauii NS
Escherichia coli (´)
Flavonols Bifidobacterium adolescentis In vitro Counting on culture medium 24 h flavonol
(galangin,kaempferol,
quercetin, myricetin, or
fisetin dissolved in
dimethylsulphoxide
(DMSO); final 25 µM; final
0.1% DMSO
[168]
Galangin (´)
Kaempferol NS
Quercetin NS
Myricetin NS
Fisetin NS
Isoflavones MIC (µg/mL) In vitro Minimum InhibitoryConcentration Assay (MIC) 1 h
Concentrations ranging
from 62.5 to 1000 µg/mL [170]
Daidzein Eschericia coli 1000
Staphylococcus aureus 125
Salmonella typhimirum 1000
Lactobacillus rhamnosus 1000
Genistein Eschericia coli 1000
Staphylococcus aureus 125
Salmonella typhimirum 1000
Lactobacillus rhamnosus 1000
Nutrients 2016, 8, 78 19 of 36
Table 3. Cont.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
Flavanones MIC (µg/mL) In vitro Minimum InhibitoryConcentration Assay (MIC) 1 h
Concentrations ranging
from 62.5 to 1000 µg/mL [169]
Naringenin Eschericia coli 125
Staphylococcus aureus 62.5
Salmonella typhimirum 125
Lactobacillus rhamnosus 125
Phenolic acids MIC (µg/mL) In vitro Minimum InhibitoryConcentration Assay (MIC) 1 h
Concentrations ranging
from 62.5 to 1000 µg/mL [169]
caffeic acid Eschericia coli 500
Staphylococcus aureus 125
Salmonella typhimirum 500
Lactobacillus rhamnosus ď250
chlorogenic acid Eschericia coli 1000
Staphylococcus aureus 125
Salmonella typhimirum 1000
Lactobacillus rhamnosus ď250
o-coumaric acid Eschericia coli 250
Staphylococcus aureus 125
Salmonella typhimirum 250
Lactobacillus rhamnosus 250
p-coumaric acid Eschericia coli 500
Staphylococcus aureus 125
Salmonella typhimirum 500
Lactobacillus rhamnosus 500
Ellagitannins POMx In vitro Liquid culturing method POMx (100 mL)
comercial extract of
pomegranate at 0.01% as
well as the effect of its
main constituents (0.05%)
[175]
Extract of pomegranate
(POMx) and its
main constituents
(punicalagins, punicalins,
elagic acid, gallic acid)
L. acidophilus (+)
L. casei ssp. casei NS
L. paracasei ssp. NS
L. pentosus (+)
L. rhamnosus (+)
B. breve (+)
B. infantis (+)
B. longum NS
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Table 3. Cont.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
Extract of pomegranate
(POMx) and its
main constituents
(punicalagins, punicalins,
elagic acid, gallic acid)
B. bifidum (+)
B. animalis ssp. lactis NS
Bacteroides fragilis NS
C. perfringens (´)
Clostridium clostriidoforme NS
C. ramosum (´)
S. aureus (´)
Punicalagin
L. acidophilus NS
L. casei ssp. casei NS
L. paracasei ssp. NS
L. pentosus NS
L. rhamnosus NS
B. breve (+)
B. infantis NS
B. longum NS
B. bifidum NS
B. animalis ssp. lactis (+)
Bacteroides fragilis NS
C. perfringens (´)
Clostridium clostriidoforme (´)
C. ramosum (´)
S. aureus (´)
Punicalin
L. acidophilus NS
L. casei ssp. casei NS
L. paracasei ssp. NS
L. pentosus NS
L. rhamnosus NS
B. breve NS
B. infantis NS
B. longum NS
B. bifidum NS
B. animalis ssp. lactis (+)
Bacteroides fragilis NS
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Table 3. Cont.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
Extract of pomegranate
(POMx) and its main
constituents
(punicalagins, punicalins,
elagic acid, gallic acid)
C. perfringens NS
Clostridium clostriidoforme NS
C. ramosum NS
S. aureus NS
IN VITRO FAECAL MICROBIOTA STUDIES
Flavonols Erysipelotrichaceae (´) In vitro 16S rDNA reads 6 weeks 30 mg/kg BW/day [167]
Quercetin Ruminococcaceae NS
Clostridiaceae NS
Bacteroidaceae NS
Lachnospiraceae NS
Acidaminococcaceae NS
Eubacteriaceae NS
Prevotellaceae NS
Acholeplasmataceae NS
Lactobacillaceae NS
Graciibacteraceae NS
Clostridium aldenense NS
Clostridium hathewayi NS
Bacteroides vulgatus (+)
Clostridium clariflavum (+)
Clostridium methylpentosum NS
Clostridium sp. C9 NS
Clostridium sp. XB90 NS
Clostridium sp. MLG661 (+)
Blautia stercoris NS
Gracilibacter thermotolerans NS
Parabacteroides distansonis NS
Eubacterium cylindroides (´)
Akkermansia muciniphila NS
Bilophila wadsworthia NS
Bacteroides sp. dnLKV7 NS
Barnesiella intestinihominis NS
Bacteroides sp. S-18 NS
Bacteroides chinchillae NS
Candidatus Prevotella conceptionensis NS
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Table 3. Cont.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
Flavanols 10 h (150 mg/L) 150 mg/L and 1000 mg/L [171]
(+)-catechin Bifidobacterium spp. (+) 17 h (1000 mg/L) 150 mg/L and 1000 mg/L
Bacteroides spp. NS
Lactobacillus/Enterococcus spp. NS
Clostridium coccoides– Eubacterium
rectale group (+)
C. histolyticum group (´) In vitro Fluorescent in situhybridization (FISH)
Escherichia coli (+)
(´)-epicatechin
Bifidobacterium spp. NS
Bacteroides spp. NS
Lactobacillus/Enterococcus spp. NS
Clostridium coccoides– Eubacterium
rectale group (+)
C. histolyticum group NS
Escherichia coli NS
Flavan-3-ols Lactobacillus/Enterococcus (+) In vitro Fluorescent in situhybridization (FISH)
Samples were
collected at 0, 5, 10,
24, 30 and 48 h of
fermentation
600 mg/L [172]
2 fractions of grape seed Clostridium histolyticum (´) Human fecalmicrobiota
Anthocyanins In vitro Fluorescent in situhybridization (FISH)
0, 1, 2, 4, 5, 10, and
24 h 20 mg/L and 200 mg/L [174]
Malvidin-3-glucoside Total bacteria count (+)
Atopobium spp. (+)
Bif idobacterium spp. (+)
C. cocoides´Eubacterium rectale (+)
Bacteroides spp. (´)
Lactobacillus spp. (+)
Clostridium histolyticum (´)
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Table 3. Cont.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
Stilbenes Erysipelotrichaceae NS In vitro 16S rDNA reads 6 weeks 15 mg/kg BW/day [167]
Trans-resveratrol Ruminococcaceae NS
Clostridiaceae NS
Bacteroidaceae NS
Lachnospiraceae NS
Acidaminococcaceae NS
Eubacteriaceae NS
Prevotellaceae NS
Acholeplasmataceae NS
Lactobacillaceae NS
Graciibacteraceae (´)
Clostridium aldenense (´)
Clostridium hathewayi (´)
Bacteroides vulgatus NS
Clostridium clariflavum NS
Clostridium methylpentosum NS
Clostridium sp. C9 (´)
Clostridium sp. XB90 (+)
Clostridium sp. MLG661 (´)
Blautia stercoris NS
Gracilibacter thermotolerans (´)
Parabacteroides distansonis (´)
Eubacterium cylindroides NS
Akkermansia muciniphila NS
Bilophila wadsworthia NS
Bacteroides sp. dnLKV7 NS
Barnesiella intestinihominis NS
Bacteroides sp. S-18 NS
Bacteroides chinchillae NS
Candidatus Prevotella conceptionensis NS
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Table 3. Cont.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
Phenolic acids Total bacteria count (+) In vitro Fluorescent in situhybridization (FISH)
0, 1, 2, 4, 5, 10, and
24 h 150 mg/L and 1000 mg/L [174]
Gallic acid Atopobium spp. (+)
Bif idobacterium spp. (+)
C. cocoides´Eubacterium rectale (+)
Bacteroides spp. (´)
Lactobacillus spp. (+)
Clostridium histolyticum (´)
Ellagitannins Total bacteria (+) In vitro
batch-culture fermentation
system inoculated with fecal
samples from healthy
individuals, FISH
Samples collected at
0, 5, 10, 24 and 48 h
POMx (1.5 mL) and
punicalagins (250 mg)
were inoculated in stirring
batch-culture vessels (one
per treatment) containing
faecal slurry (1:10, w/v).
[175]
pomegranate by-product
(POMx) Bifidobacterium spp. (+)
Lactobacillus spp. (+)
Clostridium coccoides–Eubacterium
rectale group C. histolyticum group (+)
NS
Lignans Lactobacillus rhamnosus VTT E-97800 (+) In vitro colonmodel Counting on culture medium 0, 2, 4, 6, 8, and 24 h
8 mL of fecal suspension,
and a 16.7% (w/v) final
concentration of fresh
fecal matter
[179]
Lignins L. rhamnosus VTT E-97948 (+)
Lactobacillus paracasei VTT E-97949 (+)
Lactobacillus salivarius VTT E-981006 (+)
Bifidobacterium adolescentis VTT
E-981074, Bifidobacterium breve VTT
E-981075, Bifidobacterium longum VTT
E-96664
(+)
Lactobacillus rhamnosus VTT E-97800, (+)
L. rhamnosus VTT E-97948 (+)
IN VIVO STUDIES
Isoflavones Clostridium coccoides-Eubacteriumrectale cluster (+) In vivo
FISH and flow cytometry
analyses
2 months (Fecal
samples were
collected on day 0,
30, and 60)
100 mg/day of
isoflavones aglycon
equivalents
[170]
Lactobacillus-Enterococcus group, (+)
Faecalibacterium prausnitzii subgroup,
Bifidobacterium genus (+)
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Table 3. Cont.
Polyphenol Type Tested Bacteria Growth (+)/Inhibitory(´) Effect Type of Study Methods Used Duration Doses References
Clostridium coccoides-Eubacterium
rectale cluster (+)
Condensed Tannins Lachnospiraceae (+) In vivo
culture-independent
barcoded next generation
sequencing
3 days normal diet 1% w/w Grape SeedExtract [173]
Proanthocyanidins Clostridiales (+) 6 days treatmentdiet
Lactobacillus (+)
3 days post
treatment
control-feeding
Ruminococcaceae (+) fecessamples takendaily
Stilbenes In vivo Agar dilution method 25 days 1 mg/kg/day [179]
Resveratrol Lactobacillus (+)
Bifidobacterium (+)
Enterobacteria Diminished the increase
Stilbenes Bacteroidetes-to-Firmicutes ratio, (+) In vivo FISH and flow cytometry 12 weeks 200 mg/kg/day [180]
Resveratrol Enterococcus faecalis (´)
Lactobacillus (+)
Bifidobacterium (+)
Ellagitannins Lactobacilli (+) In vivo Agar dilution method withfecal microbiota of rats
Samples collected at
days 0, 10, 20 250 mg/kg/day [177]
Pomegranate
ellagitannins and their
microbiota-derived
metabolite urolithin A
Bifidobacterium (+)
Ellagitannins Actinobacteria (+) In vivo FISH and flow cytometry 4 weeks 1000 mg POM extract [178]
Pomegranate (POM)
ellagitannins Firmicutes (´)
Verrucomicrobia (Akkermansia
muciniphila) (+)
Butyrivibrio (+)
Enterobacter (+)
Eschericia (+)
Lactobacillus (+)
Prevotella (+)
Serratia (+)
Veillonella (+)
Collinsella (´)
NS: no significant difference, (+): increase, (´): decrease.
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5.3. Limitations for the Studies on Gut Microbiota Composition Modulation by Polyphenols
The effect of phenolic compounds on gut microbiota modulation has gained much attention in
recent years, but the influence of polyphenols on specific gut bacteria is still not clear. One of the main
limitations in previous studies is that most phenolic fractions and pure phenolic compounds have
been analyzed without considering the bioavailability and the chemistry of phenolic compounds in
the colon.
Another limitation is that the information obtained from in vitro studies about the role of
individual phenolic compounds on gut microbiota cannot be directly extrapolated to what occurs
in the physiological context of the gut ecosystem. Human and animal intervention studies involve
very high doses of individual phenolic compounds, or high amounts of foods rich in phenolic content,
neither of which represents the regular diet. Therefore, there is a lack of adequate in vivo studies.
Human intervention studies provide the best models for studying the effect of phenolic
compounds on gut microbiota modulation. However, in vivo human intervention studies hold
inevitable practical and ethical limitations. Few studies have observed the in vivo impact of phenolic
compounds on the human gut microbiota [170,173,177–180]. Of those performed, most were focused
on single polyphenol molecules and selected bacterial populations. Further in vivo research is needed
to understand the effect of phenolic compounds on gut microbiota.
There may be a wide variability in response to phenolic compounds according to the differences in
gut microbiota composition. It is difficult to understand the relationship between phenolic compounds
and gut microbiota according to these inter-individual differences, especially if there are different
diet-microbiota relations. Future studies should be done considering the inter-individual differences
in gut microbiota while studying effect of phenolic compounds on gut microbiota modulation from
the immunological point of view.
After a thorough review of the latest studies on the effect of phenolic compounds on gut
microbiota, it can be stated that phenolic compounds and their metabolites contribute to beneficial
gastrointestinal health effects by modulating gut microbial balance with the simultaneous inhibition
of pathogens and stimulation of beneficial bacteria. These latest studies indicate that the concept of
prebiotics is not limited to non-digestible carbohydrates, but also applies to phenolic compounds
that have the ability to show prebiotic action [9,48,168,171,177]. Therefore, the regular consumption
of phenolic compound–rich foods in a diet may beneficially balance the gut microbiota and exert
beneficial health effects.
6. Conclusions
The interactions between dietary components, especially phenolic compounds and gut microbiota,
have gained much attention due to their relevance to bioavailability and human health. Even though
there are a number of important studies on this topic, the data presented in these papers are generally
focused on the one-way relationship between phenolics and gut microbiota, or on bioavailability.
On the other hand, this review presents an overview of the reciprocal relationship of all the subclasses of
phenolic compounds and gut microbiota, as well as the relevance of these interactions to bioavailability
and human health.
When the studies are investigated, it is clear that there are some limitations and problems with
respect to the present applications and results. For example, the studies presented in the literature
largely investigated the biotransformation of phenolic compounds in a food matrix. However, studies
using pure phenolic compounds are lacking, making it difficult to understand the exact mechanism
of each individual compound. On the other hand, phenolic compounds are biotransformed by gut
microbiota generating phenolic metabolites which may have different bioavailability in comparison to
their parent compounds. Moreover, there are some limitations for the in vivo studies including ethical
and economical issues, their complicated nature during application, and difficulties in translating the
in vitro data into in vivo conditions.
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Apart from the concerns noted above, studies focusing on the effect of two-way mutual
interactions between gut microbiota and phenolic compounds are critical, as these results may lead
to new information with respect to health. Indeed, future studies are still required to understand
this complicated mechanism. The fact that phenolic compounds may balance the gut microbiota and
contribute to gastrointestinal health, and may indeed exert prebiotic activity, makes it clear that it
is important to clarify these mechanisms specifically to understand which bacteria will affect which
phenolic compounds.
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3,4-DHPPA 3,4-dihydroxyphenylpropionic acid
3-HPPA 3-hydroxyphenylpropionic acid
4-HPPA 4-hydroxyphenylpropionic acid
3-HBA 3-hydroxybenzoic acid
4-HBA 4-hydroxybenzoic acid
3,4-DHPPA 3,4-dihydroxyphenylacetic acid
3-HPAA 3-hydroxyphenylacetic acid
4-HPAA 4-hydroxyphenylacetic acid
FISH fluorescent in situ hybridisation
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